Researchers from University of Edinburgh and University of Aberdeen in the UK found that a drug - known as melatonin - appeared to prevent pain caused by chemotherapy damage to nerves by blocking the harmful effects on nerve health.
They focused on a common condition known as chemotherapy-induced neuropathic pain (CINP), which causes tingling and pain sensation to touch and cold temperatures that can be severe enough to cause patients to limit their chemotherapy treatment.
CINP affects almost 70 per cent of patients undergoing chemotherapy and can have severe impact on quality of life.
Researchers showed that melatonin given prior to chemotherapy limited the damaging effect on nerve cells and the development of pain symptoms.
Melatonin did not alleviate pain when CINP had already developed, suggesting that its potential benefits could be as prevention rather than cure, researchers said.
They noted that meltdown treatment did not interfere with the beneficial anticancer effects of chemotherapy in human breast and ovarian cancer cells.
The study was published in the Journal of Pineal Research.
Disclaimer: No Business Standard Journalist was involved in creation of this content
